Everything below concerns lyophilized powder. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-07-07. Numbers and descriptions here follow the published literature rather than marketing material.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Handling guidance for melanotan II follows general practice for small synthetic peptides rather than a product-specific monograph. Lyophilized powder is typically kept at minus twenty degrees Celsius or colder, protected from light and moisture, because warmth and humidity accelerate degradation. Once reconstituted, solutions are usually refrigerated and used within a short window, as hydrolysis and microbial growth both become concerns. Repeated freeze-thaw cycles are generally avoided. These conventions come from laboratory peptide chemistry and not from formal stability studies on this specific compound.
Analytical confirmation of identity relies on mass spectrometry, most often coupled to liquid chromatography. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and provides a purity estimate based on peak area. Electrospray ionization mass spectrometry then confirms the expected molecular mass, while tandem mass spectrometry can map the fragment sequence. For research-grade material, these two techniques together form the standard minimum. Purity figures reported by vendors are frequently not traceable to an independent laboratory.
Independent verification is central to quality control because the compound is not produced under pharmaceutical manufacturing standards. Third-party laboratories can measure purity, identity, residual solvents, and microbial contamination, though the scope of testing varies between services. Reported analyses of vendor samples have shown batch-to-batch variation in peptide content and the presence of truncated or oxidized species. How much of this variation reflects synthesis conditions versus storage and shipping is not well characterized. No harmonized reference standard exists for the material as sold.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Unapproved for therapeutic use | No marketing authorisation from major agencies |
| Legal classification | Varies by jurisdiction | Prescription-only or controlled in several countries |
| Common synonyms | Melanotan II; MT-II | Also referenced by catalogue codes |
| Typical analytical method | Reverse-phase HPLC | Often paired with mass spectrometry |
| Primary literature focus | Receptor pharmacology | Pigmentation and melanocortin signalling |
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or oxidised impurities. Mass spectrometry, most often coupled to liquid chromatography, confirms molecular mass and detects substitutions that chromatography alone may miss. Amino acid analysis and peptide mapping supply additional structural evidence, while nuclear magnetic resonance is reserved for full structural confirmation. Laboratories that examine samples sold online report wide variation in actual content, with some vials containing little or none of the labelled material.
Melanotan-2 appears on the World Anti-Doping Agency prohibited list within the peptide hormone class, and several national regulators treat it as an unapproved prescription substance. Some countries restrict importation or sale for personal use. Because the compound is widely traded as a research chemical, the practical legal picture differs between jurisdictions and shifts over time. Human safety data covering long periods are limited, and whether repeated pigmentation changes carry any lasting risk to melanocytes remains an open question.
Lyophilised melanotan-2 is comparatively robust when kept dry, cold and dark, and a desiccated powder stored at minus twenty degrees Celsius or below is generally expected to retain its chemical integrity for extended periods. In solution the peptide is far less stable, with degradation proceeding through oxidation of tryptophan and histidine residues, hydrolysis adjacent to the lactam bridge, and aggregation at higher concentrations. Repeated freeze-thaw cycling accelerates loss of the parent peak. Working aliquots are therefore prepared once, held cold, and used without letting the stock return to ambient temperature.
Quality assessment of research-grade peptide rests mainly on reversed-phase high-performance liquid chromatography for purity and on mass spectrometry for identity confirmation. A single main peak above a stated threshold, commonly ninety-eight percent by peak area, is the usual release criterion applied by suppliers. Independent analyses commissioned by laboratories and consumer organisations have repeatedly reported discrepancies between label claims and measured content, including truncated sequences, residual trifluoroacetate, and lower-than-declared peptide mass. Those findings do not establish that every supplier is unreliable, but they indicate that purity figures printed on a vial are claims requiring verification rather than settled facts.
Regulatory treatment varies by jurisdiction and has changed over time. In several countries the peptide is handled as an unapproved prescription medicine, and import or sale for human use is restricted, while elsewhere it falls under poisons or controlled-substance schedules. Enforcement activity against online vendors has been reported in Australia, New Zealand, the United Kingdom and the United States. Scholarly writing discusses melanotan-2 chiefly as an experimental tool and as a case study in unregulated peptide supply, and its precise legal position in any given country should be checked against current national schedules.
=== SPR emission === When the surface plasmon wave interacts with a local particle or irregularity, such as a rough surface, part of the energy can be re-emitted as light. This emitted light can be detected behind the metal film from various directions.
=== Critical response === The review aggregator website Rotten Tomatoes reported a 100% approval rating with an average rating of 7.7/10, based on 24 critic reviews. The website's critics consensus reads, "Case closed—this Matlock reboot is a winner thanks to the ever reliable Kathy Bates and the intriguing wrinkle it puts on the legendary series' original concept." Metacritic, which uses a weighted average, assigned a score of 73 out of 100 based on 12 critics, indicating "generally favorable" reviews.
The earliest description and illustration of gigantomastia dates to 1669. In July of that year the Plymouth physician William Durston wrote to the Royal Society, reporting the case of a patient named Elizabeth Travers. Durston's account was soon published in the Society's Philosophical Transactions, and includes the following account of the onset of symptoms:Elizabeth Treves, [sic] 23. or 24. years of age, fair of complexion, brown-hair'd, of an healthy constitution, low of stature, of honest repute, but of mean and poor parentage, near this Town [Plymouth], was on Friday July 3d, 1669 in good health, and went well to bed, where she took as good rest and sleep, as ever before, but in the morning, when she awaken'd, and attempted to turn herself in her bed, was not able, finding her Breasts so swell'd, that she was affrighted to an astonishment. Then endeavoring to sit up, the weight of her Breasts fastned her to her bed; where she hath layn ever since, yet without all pain and weakness either in her Breasts, or in any other part.Durston later wrote to the Society to report that Travers had died on October 21 of the same year, four months after the onset of enlargement. One breast removed after the woman's death weighed 64 lb (29 kg).
Sources: en.wikipedia.org
=== Similarity to edible species === A. phalloides is similar to the edible paddy straw mushroom (Volvariella volvacea) and A. princeps, commonly known as "white Caesar". Some may mistake juvenile death caps for edible puffballs or mature specimens for other edible Amanita species, such as A. lanei, so some authorities recommend avoiding the collecting of Amanita species for the table altogether. The white form of A. phalloides may be mistaken for edible species of Agaricus, especially the young fruitbodies whose unexpanded caps conceal the telltale white gills; all mature species of Agaricus have dark-colored gills. In Europe, other similarly green-capped species collected by mushroom hunters include various green-hued brittlegills of the genus Russula and the formerly popular Tricholoma equestre, now regarded as hazardous owing to a series of restaurant poisonings in France. Brittlegills, such as Russula heterophylla, R. aeruginea, and R. virescens, can be distinguished by their brittle flesh and the lack of both volva and ring. Other similar species include A. subjunquillea in eastern Asia and A. arocheae, which ranges from Andean Colombia north at least as far as central Mexico, both of which are also poisonous.
In his final years in high school Bolsonaro was admitted to the Escola Preparatória de Cadetes do Exército (the prep school of the Brazilian Army), which he entered in 1973. In 1974 he went to the Military Academy of Agulhas Negras (Brazil's premier military academy), graduating in 1977 as an artillery officer. He served in the 9th Field Artillery Group, in Nioaque, Mato Grosso do Sul. Later, he studied at the Army Physical Training School in Rio de Janeiro and served in the 21st Field Artillery Group and the 8th Paratrooper Field Artillery Group, from the Paratrooper Brigade, also based in Rio. His superior officers described him as "aggressive" and criticized his "excessive ambition for financial and economic gain". This assessment referred to Bolsonaro's attempt to mine gold in Bahia, though he later claimed the activity was merely a "hobby and mental hygiene". In 1987 he studied in the Officers Improvement School, where he completed the Artillery Advanced Course. Bolsonaro first caught the public's attention in 1986 when he wrote an article published in the news magazine Veja. He complained about low military salaries and claimed that the High Command was dismissing officers due to budgetary cuts, not because they were displaying "deviations of conduct", as the command had told the press. Despite being reprimanded by his superiors, Bolsonaro received praise from fellow officers and wives of military men, becoming a household name for supporters who were growing disenchanted with Brazil's new civilian democratic government.
Team Fortress Classic is a 1999 first-person shooter game developed by Valve and published by Sierra Studios. It was originally released in April 1999 as a mod for Valve's 1998 Windows game Half-Life, and is based on Team Fortress, a mod for the 1996 game Quake. In Team Fortress Classic, two teams compete in online multiplayer matches. Players choose one of nine classes, each with different skills. The scenarios include capture the flag, territorial control, and escorting a "VIP" player. Valve hired the developers of the Team Fortress mod to develop Team Fortress Classic. It received generally positive reviews, although the graphics were a point for criticism. In 2000, Valve released a standalone version, Team Fortress 1.5, with new character models, maps and other features. Team Fortress 2 was released in 2007.
== Chemistry == AH-7921 is commonly found as an off-white solid with a melting point between 215–216º Celsius. It is one single covalently bonded unit with 4 rotatable bonds. It also has two hydrogen bond acceptors, and one hydrogen bond donor.
Sources: en.wikipedia.org
Major regulatory agencies have not approved it for any indication. Some countries permit it only under prescription frameworks, while others classify it as a controlled substance.
Much of the evidence comes from case reports and accounts of unregulated use rather than controlled trials. Differences in product purity and dosing add further variability.
Laboratory work focuses on receptor binding and cellular signalling. Observational reports document outcomes after use, and analytical chemists examine samples to assess content and purity.
The lyophilized powder is generally held at minus twenty degrees Celsius or below, away from light and moisture. Reconstituted solutions are typically refrigerated and used quickly. These practices derive from general peptide handling rather than a formal stability study.